Is AXGN or BLFS more undervalued in 2026?

CirclFi compares AxoGen, Inc. (AXGN) and BioLife Solutions, Inc. (BLFS) using 13 institutional-grade valuation models. AXGN has a Quality of Company score of 7.9/10 while BLFS scores 7.1/10.

Which is a better buy — AXGN or BLFS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do AXGN and BLFS valuations compare?

AXGN at $39.48 and BLFS at $24.92 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

AXGN vs BLFS Valuation Comparison 2026 — Intrinsic Value Analysis

AXGN

Electromedical & Electrotherapeutic Apparatus

AxoGen, Inc.

Quality

7.9

out of 10

Value Trap

SAFE

Price

$39.48

Last close

Models

11/13

Active

BLFS

Electromedical & Electrotherapeutic Apparatus

BioLife Solutions, Inc.

Quality

7.1

out of 10

Value Trap

SAFE

Price

$24.92

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	AXGN Fair Value	AXGN Upside	BLFS Fair Value	BLFS Upside
Bayesian DCF	Intrinsic	$0.73	-98.2%	$2.87	-88.5%
Earnings Power Value	Intrinsic	$8.59	-80.2%	$3.00	-85.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for AXGN vs BLFS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AXGN vs BLFS — Which Stock Is More Undervalued?

AXGN scores higher with a 7.9/10 quality rating vs BLFS's 7.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing AxoGen, Inc. (AXGN) and BioLife Solutions, Inc. (BLFS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AXGN currently trades at $39.48 with a QOC of 7.9/10, while BLFS trades at $24.92 with a QOC of 7.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).